Cardinal Health’s Fair Value Estimate has seen a moderate uplift, increasing from $180.46 to $189.36 per share as a result of shifting analyst views. This change follows strong quarterly performance and new operational guidance, which reinforces optimism in the company’s growth prospects while also highlighting areas for careful observation. Stay tuned to learn how you can remain informed as Cardinal Health’s evolving narrative continues to shape price target updates.
Stay updated as the Fair Value for Cardinal Health shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Cardinal Health.
🐂 Bullish Takeaways
Evercore ISI, led by analyst Elizabeth Anderson, raised its price target for Cardinal Health to $220 from $190 while maintaining an Outperform rating. The firm highlighted strong fiscal performance at the start of FY26, noting robust execution across all segments, a 37% year-over-year adjusted operating income increase, and margin recovery in Global Medical Products. The analyst suggested there is additional upside potential based on current momentum.
BofA increased its price target to $216 from $180 and reiterated a Buy rating following what it described as “strong” Q1 results. BofA expressed continued confidence in Cardinal Health’s core pharmaceutical segment and the company’s ability to meet its long-term adjusted EPS growth targets of 12% to 14%.
Analyst commentary across these firms rewards Cardinal Health for its execution, particularly in Pharma and Global Medical Products, as well as for operational discipline and growth delivery.
🐻 Bearish Takeaways
Leerink, via analyst Michael Cherny, adjusted its price target down slightly to $186 from $188 but kept an Outperform rating. The firm acknowledged recent share weakness was not unwarranted and cited disappointment in Pharma growth versus expectations. Leerink noted that high investor expectations following a robust Investor Day set a challenging benchmark. However, the firm views the subsequent operational guidance increase as evidence of ongoing enterprise strength.
The more cautious commentary centers on valuation concerns, with some skepticism that the stock’s current multiples fully reflect its underlying growth stability. Near-term headwinds in Pharma growth have also been acknowledged as risks to monitor.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
NYSE:CAH Community Fair Values as at Oct 2025
Cardinal Health is preparing to report earnings, with consensus expectations for earnings per share at $2.17. The report is part of a broader set of corporate results that investors are anticipating before the market opens.
The Trump administration is planning a new inquiry into drug pricing policies of U.S. trading partners, which could potentially affect major pharmaceutical distributors such as Cardinal Health.
Cardinal Health has launched the Kendall SCD SmartFlow Compression System in international markets. This new product provides advanced patient monitoring and therapy tracking, supporting efforts to prevent venous thromboembolism.
The company has announced the development of a highly automated forward distribution center in Indianapolis, Indiana. This facility is expected to create over 100 new jobs and will enhance Cardinal Health’s national pharmaceutical logistics network.
The Fair Value Estimate has increased moderately, rising from $180.46 to $189.36 per share.
The Discount Rate remains unchanged at 6.78%.
Revenue Growth projections have risen slightly, moving from 8.97% to 9.20%.
The Net Profit Margin has declined marginally, decreasing from 0.78% to 0.77%.
The Future P/E Ratio has increased from 22.49x to 23.60x, reflecting a modest uplift in expected valuation multiples.
Narratives offer a smarter, story-driven approach to making investment decisions. Rather than relying solely on numbers, a Narrative connects Cardinal Health’s real-world developments with its financial forecast and Fair Value. You can access Narratives on Simply Wall St’s popular Community page, where millions of investors contribute their perspectives. By comparing Fair Value with the current Price, Narratives are updated in real time as news and earnings are announced, supporting you in deciding when to buy or sell with confidence.
Visit the original Narrative on Cardinal Health to stay informed about:
The ways in which core pharmaceutical and specialty trends, together with automation, are influencing future earnings and margin improvements.
The impact that changing regulatory pressures and competitive risks could have on the long-term growth outlook and Fair Value.
How revised financial targets, market catalysts, and expert consensus shape buy or sell signals as new information becomes available.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CAH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
